PerOlof Gunnesson - Mendus AB Advisor Contracts

All Insiders . Sweden . 
Stock . Mendus AB . Stakeholders . Insider . PerOlof Gunnesson
IMMU Stock  SEK 8.48  0.23  2.64%   

Insider

PerOlof Gunnesson is Advisor Contracts of Mendus AB
Age 78
Phone46 87 32 84 00
Webhttps://www.mendus.com

Mendus AB Management Efficiency

The company has return on total asset (ROA) of (0.1114) % which means that it has lost $0.1114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2053) %, meaning that it generated substantial loss on money invested by shareholders. Mendus AB's management efficiency ratios could be used to measure how well Mendus AB manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Malin CarlssonAlligator Bioscience AB
55
Julie SilberAlligator Bioscience AB
N/A
Sylvie RyckebuschBioInvent International AB
N/A
MSc BAMoberg Pharma AB
43
Marie MobergMoberg Pharma AB
N/A
Susanne LagerlundCantargia AB
N/A
Kjell SjstrmCantargia AB
N/A
Stefan MBABioInvent International AB
60
Gunilla WengstrmMoberg Pharma AB
N/A
Linda HolmstromOncopeptides AB
N/A
Kerstin StrinnholmMoberg Pharma AB
63
Johanna ChristensenCantargia AB
N/A
Dominique TersagoCantargia AB
61
Adnan DeronicCantargia AB
N/A
Bjrn FrendusBioInvent International AB
50
Sren BregenholtAlligator Bioscience AB
52
Marie SvenssonAlligator Bioscience AB
59
Peter MadsenCantargia AB
N/A
Peter NygrenOncopeptides AB
64
Nina ValkamaCantargia AB
N/A
Ingrid TeigeBioInvent International AB
N/A
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden. Mendus AB (IMMU) is traded on Stockholm Exchange in Sweden and employs 31 people.

Management Performance

Return On Equity-0.21
Return On Asset-0.11

Mendus AB Leadership Team

Elected by the shareholders, the Mendus AB's board of directors comprises two types of representatives: Mendus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mendus. The board's role is to monitor Mendus AB's management team and ensure that shareholders' interests are well served. Mendus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mendus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, Bus Advisor
Leopold Bertea, Chief Officer
Lotta Ferm, Chief Officer
Erik Manting, Chief Officer
Jeroen MD, Chief Officer
PerOlof Gunnesson, Advisor Contracts
Alex MD, CoFounder Officer

Mendus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mendus AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.21
Return On Asset-0.11
Operating Margin(69.15) %
Current Valuation607.17 M
Shares Outstanding199.4 M
Shares Owned By Insiders57.54 %
Shares Owned By Institutions11.78 %
Price To Earning(4.53) X
Price To Book1.13 X
Price To Sales354.29 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Mendus Stock Analysis

When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY